Ovarian Cancer and Related Gynecologic Malignancies
The sponsor’s clinical research is centered on ovarian cancer and closely related tumors of the fallopian tube and primary peritoneum, with attention to both advanced and recurrent disease settings.
- Advanced high-grade ovarian cancer
- Fallopian tube cancer
- Primary peritoneal cancer
- Clear cell carcinoma of the ovary
Research activity also includes disease subtypes defined by FIGO stage IIIA, IIIB, IIIC, and IV, reflecting a focus on clinically complex gynecologic oncology populations.
HRD-positive Tumor Biology
One major area of interest is homologous recombination deficiency-associated disease, particularly HRD-positive high-grade ovarian cancer after primary tumor debulking with no residual tumor mass.
- Homologous recombination deficiency
- Maintenance therapy in ovarian cancer
- Recurrence-free survival
- Post-debulking residual disease assessment
This research domain addresses treatment strategies for patients with biologically defined disease who require long-term disease control after initial surgical management.
Low-grade Serous Ovarian Cancer and Recurrent Disease
The sponsor also funds studies in recurrent platin-sensitive low-grade serous ovarian cancer and associated tubal and peritoneal cancers, highlighting interest in a distinct therapeutic subgroup with specific relapse patterns.
- Low-grade serous ovarian cancer
- Platin-sensitive recurrence
- Recurrent gynecologic cancer
- Disease control in relapsed settings
These studies focus on patients whose disease course requires strategies tailored to recurrence risk and prior treatment sensitivity.
Immunotherapy and Targeted Maintenance Treatment
Clinical research activity includes pembrolizumab-based treatment in low-grade serous ovarian cancer and niraparib-based maintenance approaches in advanced HRD-positive disease.
- Immune checkpoint inhibition
- PARP inhibitor maintenance
- Progression-free survival
- Post-chemotherapy maintenance strategies
These therapeutic interests reflect a focus on extending disease control through immunotherapy and molecularly guided maintenance treatment in gynecologic oncology.
